Identification of SLC7A11‐AS1/SLC7A11 pair as a ferroptosis‐related therapeutic target for hepatocellular carcinoma
Journal of Cellular and Molecular Medicine · 2024-07 · 28 (13)
DOI: 10.1111/jcmm.18496 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 10.07.2024. Verfasst von Xiao Yuan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Bio-Resource and Eco-Environment of Ministry of Education, School of Life Science, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Ferroptosis, Carcinoma, Hepatocellular, Liver Neoplasms, Amino Acid Transport System y+. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC), a prevalent malignancy worldwide, poses significant challenges in terms of prognosis, necessitating innovative therapeutic approaches. Ferroptosis offers notable advantages over apoptosis, holding promise as a novel therapeutic approach for HCC complexities. Moreover, while the interaction between long non‐coding RNAs (lncRNAs) and mRNAs is pivotal in various physiological and pathological processes, their involvement in ferroptosis remains relatively unexplored. In this study, we constructed a ferroptosis‐related lncRNA‐mRNA correlation network in HCC using Pearson correlation analysis. Notably, the SLC7A11‐AS1/SLC7A11 pair, exhibiting high correlation, was identified. Bioinformatics analysis revealed a significant correlation between the expression levels of this pair and key clinical characteristics of HCC patients, including gender, pathology, Ishak scores and tumour size. And poor prognosis was associated with high expression of this pair. Functional experiments demonstrated that SLC7A11‐AS1, by binding to the 3′UTR region of SLC7A11 mRNA, enhanced its stability, thereby promoting HCC cell growth and resistance to erastin‐ induced ferroptosis. Additionally, in vivo studies confirmed that SLC7A11‐AS1 knockdown potentiated the inhibitory effects of erastin on tumour growth. Overall, our findings suggest that targeting the SLC7A11‐AS1/SLC7A11 pair holds promise as a potential therapeutic strategy for HCC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Bio-Resource and Eco-Environment of Ministry of Education, School of Life Science, Sichuan University, Chengdu, China.
ORCID-Profile: Xiao Yuan
Zitieren
APA
Yuan, X., Wang, Y., Jiao, S., Gao, H., Zhang, M., Wang, X., Zhou, X., Wu, C., & Bao, J. (2024). Identification of SLC7A11‐AS1/SLC7A11 pair as a ferroptosis‐related therapeutic target for hepatocellular carcinoma. Journal of Cellular and Molecular Medicine, 28(13). https://doi.org/10.1111/jcmm.18496
Vancouver
Yuan X, Wang Y, Jiao S, Gao H, Zhang M, Wang X, et al. Identification of SLC7A11‐AS1/SLC7A11 pair as a ferroptosis‐related therapeutic target for hepatocellular carcinoma. Journal of Cellular and Molecular Medicine. 2024;28(13). doi:10.1111/jcmm.18496
BibTeX
@article{Yuan2024,
author = {Yuan, Xiao and Wang, Yida and Jiao, Sitong and Gao, Huanhuan and Zhang, Mengqian and Wang, Xin and Zhou, Xunyu and Wu, Chuanfang and Bao, Jinku},
title = {Identification of SLC7A11‐AS1/SLC7A11 pair as a ferroptosis‐related therapeutic target for hepatocellular carcinoma},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
volume = {28},
number = {13},
doi = {10.1111/jcmm.18496}
}
EUVIMED